A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis

Inclusion Criteria:

- You must have active chronic plaque psoriasis for at least 6 months prior to entry
into the study

- You are a candidate for systemic therapy and/or phototherapy

- You must have active plaque psoriasis covering at least 12% body surface area

- You must have Psoriasis Area and Severity Index (PASI) score of at least 12

- You must have Static Physician's Global Assessment (sPGA) score of at least 3

Exclusion Criteria:

- You must not have received a biologic agent/monoclonal antibody within 8 weeks prior
to entry into the study

- You must not have prior treatment with an oral Janus kinase (JAK) inhibitor

- You must not have received a systemic psoriasis (Ps) therapy within 4 weeks prior to
entry into the study

- You must not have received a phototherapy within 4 weeks prior to entry into the
study

- You must not have received a topical Ps therapy with psoralens within 4 weeks prior
to entry into the study

- You must not be pregnant or nursing

- If female of childbearing potential or a male, and do not agree to use 2 forms of
highly effective methods of birth control for at least 28 days following the last
dose of investigational product

- You must not have had symptomatic herpes zoster or herpes simplex infection within 12
weeks or have a history of disseminated/complicated herpes zoster

- You must not have evidence of active infection, such as fever ≥38.0ºC (100.4ºF)

- You must not have a history of active hepatitis B, hepatitis C, or human
immunodeficiency virus (HIV)

- You must not be immunocompromised and, in the opinion of the investigator, are at an
unacceptable risk for participating in the study

- You must not have known history hypogammaglobulinemia

- You must not have had a serious systemic or local infection within 12 weeks prior to
entry into the study

- You must not have been exposed to a live vaccine within 12 weeks prior to entry into
the study, or expected to need/receive a live vaccine (including herpes zoster
vaccination) during the course of the study

- You must not have had household contact with a person with active tuberculosis (TB)
and did not receive appropriate and documented prophylaxis for TB

- You must not have a serious and/or unstable illness that, in the opinion of the
investigator, poses an unacceptable risk for the your participation in the study

- You must not have or have had a history of lymphoproliferative disease; or signs or
symptoms suggestive of possible lymphoproliferative disease, including
lymphadenopathy or splenomegaly; or active primary or recurrent malignant disease; or
been in remission from clinically significant malignancy for less than 5 years

- You must not have a history of chronic alcohol abuse or intravenous (IV) drug abuse
within the last 2 years

- You must not have donated blood of more than 500 mL within 4 weeks

- You must not have received a topical Ps treatment within 2 weeks prior to entry into
the study

- Exceptions:

- class 6 (mild, such as desonide) or class 7 (least potent, such as
hydrocortisone) topical steroids used on the face, axilla, palms, soles, and/or
genitalia

- non-medicated shampoos (for example, that do not contain corticosteroids, coal
tar, or vitamin D3 analogues)

- emollients that do not contain alpha or beta hydroxyl acids